Cutting-edge advances of renal carcinoma diagnosis and treatment in 2024: multi-dimensional breakthroughs from basic science to clinical application
10.3760/cma.j.cn112330-20250320-00108
- VernacularTitle:肾肿瘤诊疗2024年前沿进展——从基础到临床的多维度突破
- Author:
Xiaolei SHI
1
;
Zhenjie WU
;
Linhui WANG
;
Xu ZHANG
Author Information
1. 上海长海医院泌尿外科，上海 200433
- Publication Type:Journal Article
- Keywords:
Kidney neoplasms;
Artificial intelligence;
Molecular imaging;
Telesurgery;
Targeted therapy and immunotherapy;
Radiotherapy
- From:
Chinese Journal of Urology
2025;46(5):325-330
- CountryChina
- Language:Chinese
-
Abstract:
Renal carcinoma，a common malignant tumor of the urinary system，poses a significant disease burden . With innovations in artificial intelligence（AI）deep learning algorithms and the expanded clinical use of domestically developed surgical robots，renal carcinoma diagnosis and treatment have seen multi-dimensional breakthroughs. In molecular imaging and pathology diagnosis，AI drives multi-omics fusion diagnosis，while molecular imaging guides precise treatment. In surgical technology，5G-enabled telesurgery transcends geographical limits，and immersive virtual reality technology boosts surgical accuracy. Targeted therapy and immunotherapy revolutionizes advanced renal carcinoma treatment and opens up new therapeutic frontiers. Radiotherapy and energy therapy have become more precise. Despite these advances，bottlenecks persist in diagnosis and treatment. Future progress requires focusing on technological integration，clinical translation，and exploration of energy-based therapies to transition from "precise" to "intelligence" in renal carcinoma diagnosis and treatment.
